Send a Tweet
Most Popular Choices
Share on Facebook 39 Share on Twitter 1 Printer Friendly Page More Sharing
Exclusive to OpEdNews:
Sci Tech    H4'ed 7/2/13

Cancer Immunotherapy from Dr. Yamamoto

By       (Page 1 of 4 pages)   2 comments
Become a Premium Member Would you like to know how many people have read this article? Or how reputable the author is? Simply sign up for a Advocate premium membership and you'll automatically see this data on every article. Plus a lot more, too.
Author 30652
Follow Me on Twitter     Message Jeffrey Dach
Become a Fan
  (12 fans)

Link to original article

Left Image: CAT SCan Brain Showing enhancing metastatic lesions from breast-cancer primary. Courtesy of wikimedia commons.

This article explores the work of Dr. Yamamoto, who discovered the Macrophage-Activating Factor (GcMAF) in 1990 at the Socrates Institute in Philadelphia (4).  Since then, Dr. Yamamoto has published three human clinical trials showing remarkable results for breast (5), colo-rectal (10), and prostate cancer(11).

What is MAF -- Macrophage-Activating Factor?

MAF is a protein that activates our macrophages, the microscopic white cells that kill invading microbes and cancer cells.  MAF is made from a precursor protein called the Gc protein.

Cancer is Clever -- It Inactivates Our Immune System

In a way, cancer cells are clever little devils because they disable our immune system in order to enhance their own survival.  Dr. Yamamoto discovered that cancer cells do this by secreting an enzyme called Nagalase, which prevents the precursor protein Gc from being converted to MAF.  This Nagalase-enzyme activity can actually be measured in cancer patients, and greater tumor burden corresponds with higher Nagalase enzyme activity (as one would expect).  Elimination of the tumor results in reduction of Nagalase activity to lower, more normal values. (5)
Dr. Yamamoto devised a technique for restoring Gc-protein activity, which creates the most potent macrophage-activating factor ever discovered, having no adverse effects.  He called it  GcMAF.  Macrophages treated in vitro with GcMAF (100 pg/ml) are highly effective at killing breast-cancer cells.

GcMAF for Metastatic Breast Cancer -- Human Trial

Dr. Yamamoto then studied his GcMAF in human metastatic breast-cancer patients with weekly injections of 100 ng of GcMAF (5).   Dr. Yamamoto found that over time, as treatment with GcMAF  progresses, the MAF-precursor activity of patient Gc protein increased, and the serum Nagalase decreased (5).  After 5 months of weekly GcMAF injections, the cancer patients' elevated Nagalase activity had returned to normal levels, same as healthy controls.  Over the next four years, these sixteen treated metastatic breast-cancer patients remained cancer free with no recurrence (5).   In 2008, Dr. Yamamoto published his landmark study on human breast cancer.(5)

GcMAF for Metastatic Colorectal Cancer -- Human Trial

In 2008, Yamamoto published his study  on 8 patients with metastatic colorectal cancer.  They all had significant metastatic disease after primary resection (10).  Nagalase activity fell to normal levels with GcMAF injections, and remained low with no cancer recurrence over 7 years of observation.  This was supported by serial CAT scans that remained negative.

GcMAF for Metastatic Prostate Cancer -- Human Trial

Dr. Yamamoto studied GcMAF in 16 patients with metastatic prostate cancer with excellent results.  Nagalase activity declined to normal, and there was no evidence of tumor recurrence over 7 years of observation. (10)

"Sixteen nonanemic prostate-cancer patients received weekly administration of 100 ng of GcMAF. As the MAF-precursor activity increased, their serum Nagalase activity decreased. Because serum Nagalase activity is proportional to tumor burden, the entire time-course analysis for GcMAF therapy was monitored by measuring the serum Nagalase activity. After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had very low serum Nagalase levels equivalent to those of healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years." Quote from abstract of 2008 paper (10). 

The Saisei Mirai Clinic in Kobe, Japan

Toshio Inui, MD, of the Saisei Mirai Clinic in Kobe, Japan, has treated over 345 patients with GcMAF combined with other modalities, and reports his results in  Anticancer Research July 2013 (2,3). 

At the Saisei Mirai clinic, Dr. Inui treats cancer patients with GcMAF immunotherapy in combination with other related therapies, such as intravenous vitamin C, alpha-lipoic acid, hyperthermia, and LDN (low-dose naltrexone). Dr Inui says his results are mixed, and describes his treatment as "hopeful."  He presents three cases in which treatment was remarkably effective:

Quoted from Anticancer Research (3).

Patient 1. A 71-year-old man was diagnosed with thymic carcinoma with lung metastasis. The patient received 24 weeks of the integrative immunotherapy. No progression of the cancer was found 12 months after completion of the therapy.

Patient 2. A 74-year-old man was diagnosed with prostate cancer with multiple bone metastases. He received 12 weeks of the integrative immunotherapy combined with hyperthermia therapy. Bone scintigram results nine months after initiation of the therapy were normal and metastatic tumors had disappeared.

Patient 3. A 72-year-old woman was diagnosed with metastatic liver cancer after sigmoidectomy and bilateral oophorectomy. She received 24 weeks of the integrative immunotherapy combined with 55 Gy of radiation. There was no evidence of local recurrence or metastatic disease on Positron-Emission Tomography (PET) and Computed Tomography (CT) scans 12 months after initiation of the therapy.

Next Page  1  |  2  |  3  |  4

(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).


Valuable 2   Must Read 1   Well Said 1  
Rate It | View Ratings

Jeffrey Dach Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Jeffrey Dach MD is a physician and author of three books, Natural Medicine 101, and Bioidentical Hormones 101, and Heart Book all available on Amazon, or as a free e-book on his web sites. Dr. Dach is founder and chief medical officer of (more...)

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
   (Opens new browser window)

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Failed Hatchet Job on Larry King, Suzanne Somers, Knockout

Bioidentical Hormones on Oprah, Are They Safe?

Why Natural Thyroid is Better than Synthetic

Wheatgrass, Natural Medicine in the Kitchen

Fish Oil Increases Risk for Prostate Cancer, New Study?

Spontaneous Remission Cancer Breakthrough

To View Comments or Join the Conversation: